DrugPatentWatch Database Preview

Details for Patent: 8,746,242

« Back to Dashboard

Which drugs does patent 8,746,242 protect, and when does it expire?

Patent 8,746,242 protects ANORO ELLIPTA, ARNUITY ELLIPTA, BREO ELLIPTA, INCRUSE ELLIPTA, and TRELEGY ELLIPTA, and is included in five NDAs.

This patent has twenty-six patent family members in nineteen countries.

Summary for Patent: 8,746,242

Title:	Medicament dispenser
Abstract:	A medicament dispenser for use with at least one medicament carrier carrying multiple distinct medicament portions, said medicament dispenser comprising (a) a dispensing mechanism actuable for dispensing the distinct medicament portions carried by the at least one medicament carrier; (b) a mouthpiece; and (c) a cover for the mouthpiece, the cover being movably mounted to the dispenser for sequential movement from a first position, in which the mouthpiece is covered, to a second position, in which the mouthpiece is at least part-uncovered, to a third position in which the mouthpiece is uncovered; wherein the cover is adapted to couple with the dispensing mechanism such that movement of the cover from the second position to the third position, but not the first position to the second position, results in actuation of the dispensing mechanism.
Inventor(s):	Connell; Hugh Alexander (Evesham, GB), Harvey; Stephen James (Ware, GB), Tansley; Robert William (Bidford on Avon, GB)
Assignee:	Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:	11/996,762
Patent Claim Types: see list of patent claims	Composition; Device; Use;

Recent additions to Drugs Protected by US Patent 8,746,242

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER	209482	Sep 18, 2017	RX	Yes		Y

Drugs Protected by US Patent 8,746,242

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes			Y
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018		RX	Yes	Yes			Y
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-001	Aug 20, 2014		RX	Yes	Yes			Y
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014		RX	Yes	Yes			Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes			Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes			Y
Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382-001	Apr 30, 2014		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,746,242

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0515584.1	Jul 28, 2005

PCT Information
PCT Filed	July 27, 2006	PCT Application Number:	PCT/GB2006/002831
PCT Publication Date:	February 01, 2007	PCT Publication Number:	WO2007/012871

International Family Members for US Patent 8,746,242

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006273856
Brazil	PI0614568
Canada	2616193
China	101272818
Denmark	1907037
European Patent Office	1907037
Spain	2745602